Correction to: The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.
作者信息
Ramin Cody, Gierach Gretchen L, Abubakar Mustapha, Veiga Lene H S, Vo Jacqueline B, Curtis Rochelle E, Bowles Erin J Aiello, Feigelson Heather Spencer, Buist Diana S M, de Gonzalez Amy Berrington, Bodelon Clara
机构信息
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.
出版信息
Cancer Causes Control. 2023 Jan;34(1):101-102. doi: 10.1007/s10552-022-01627-1.
Abstract
摘要
相似文献
1
Correction to: The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.对《美国综合医疗系统中治疗对激素受体亚组及乳腺癌特异性死亡率的影响》的更正
Cancer Causes Control. 2023 Jan;34(1):101-102. doi: 10.1007/s10552-022-01627-1.
2
Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.按激素受体亚型、地区层面社会经济地位和医疗资源划分的个体乳腺癌结局中的种族差异。
Breast Cancer Res Treat. 2016 Jun;157(3):575-86. doi: 10.1007/s10549-016-3840-x. Epub 2016 Jun 2.
3
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.接受细胞周期蛋白依赖性激酶 4/6 抑制剂联合氟维司群治疗的激素受体阳性、HER2 阴性、晚期或转移性乳腺癌患者的总生存期：美国食品和药物管理局的汇总分析。
Lancet Oncol. 2021 Nov;22(11):1573-1581. doi: 10.1016/S1470-2045(21)00472-1. Epub 2021 Oct 14.
4
Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.2000 - 2012年美国女性乳腺癌分子亚型的筛查、治疗与乳腺癌死亡率的关联
JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130.
5
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.来曲唑：对其在绝经后乳腺癌女性中应用的药物经济学综述。
Pharmacoeconomics. 2006;24(5):495-517. doi: 10.2165/00019053-200624050-00007.
6
Integrated Analysis of mRNA-miRNA-lncRNA ceRNA Network in Human HR+/Her-2- Breast Cancer and Triple Negative Breast Cancer.人 HR+/Her-2- 乳腺癌和三阴性乳腺癌中 mRNA-miRNA-lncRNA ceRNA 网络的综合分析。
J Comput Biol. 2020 Jul;27(7):1055-1066. doi: 10.1089/cmb.2019.0152. Epub 2019 Oct 24.
7
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?我们是否更接近于能够挑选出那些可以安全地省略化疗的淋巴结阳性、激素受体阳性乳腺癌患者？
Ther Adv Med Oncol. 2022 Mar 26;14:17588359221084769. doi: 10.1177/17588359221084769. eCollection 2022.
8
Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System.美国综合医疗系统中接受治疗的精神分裂症患者的特征与医疗负担
J Ment Health Policy Econ. 2021 Jun 1;24(2):47-59.
9
Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups.HER2阳性晚期乳腺癌患者药物治疗的比较性综述，重点关注激素受体亚组。
Front Oncol. 2022 Aug 18;12:943154. doi: 10.3389/fonc.2022.943154. eCollection 2022.
10
Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland.芬兰西南部医院区乳腺癌生物学亚组的真实世界临床结局
Oncologist. 2021 Aug;26(8):e1372-e1380. doi: 10.1002/onco.13813. Epub 2021 Jun 1.
本文引用的文献
1
The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.在美国综合医疗体系中，治疗对激素受体亚组和乳腺癌特异性死亡率的影响。
Cancer Causes Control. 2022 Jul;33(7):1019-1023. doi: 10.1007/s10552-022-01589-4. Epub 2022 May 18.
Zotero 插件